Bicycle Therapeutics PLC (BCYC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Bicycle Therapeutics reported revenue of $72.6M, up 105.8% from $35.3M the year before. Net income was -$219.0M (a -301.7% net margin), or -$3.16 per diluted share. Operating margin was -340.4%. Operating activities generated -$249.7M of cash, leaving -$252.0M of free cash flow. At fiscal year end, Bicycle Therapeutics held $717.6M in total assets against $107.6M in total liabilities, including $628.1M of cash and equivalents.
Open the full interactive Bicycle Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Bicycle Therapeutics Key Stats
| Share Price | $3.63 |
|---|---|
| Market Cap | $253.4M |
| Revenue YoY Growth | +105.8% |
| 52-Week Range | $3.38 – $8.76 |
| Shares Outstanding | 69.8 million (basic, 2026 Q2) |
Bicycle Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.4M | $11.7M | $14.5M | $27.0M | $35.3M | $72.6M |
| Operating Income | -$52.0M | -$65.6M | -$116.7M | -$189.9M | -$209.9M | -$247.1M |
| Pre-Tax Income | -$51.7M | -$68.5M | -$114.2M | -$179.2M | -$173.8M | -$218.8M |
| Income Tax | -$724,000 | -$1.7M | -$1.5M | $1.5M | -$4.8M | $152,000 |
| Net Income | -$51.0M | -$66.8M | -$112.7M | -$180.7M | -$169.0M | -$219.0M |
| Diluted EPS | -$2.66 | -$2.67 | -$3.80 | -$5.08 | -$2.90 | -$3.16 |
Bicycle Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.7M | $48.0M | $887,000 | $629,000 |
| Net Income | -$59.1M | -$20.2M | -$60.8M | -$50.3M |
| Diluted EPS | -$0.85 | -$0.29 | -$0.87 | -$0.72 |
Bicycle Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $0 | $438.7M | $339.2M | $526.4M | $879.5M | $628.1M |
| Current Assets | $155.7M | $458.6M | $369.4M | $561.9M | $928.6M | $682.9M |
| Total Assets | $161.2M | $479.8M | $410.6M | $595.3M | $956.9M | $717.6M |
| Current Liabilities | $23.1M | $36.2M | $53.3M | $69.5M | $67.2M | $57.0M |
| Total Long-Term Debt | $14.5M | $29.9M | $30.3M | $30.7M | — | — |
| Total Liabilities | $65.7M | $133.5M | $139.8M | $224.4M | $163.8M | $107.6M |
| Shareholders' Equity | $95.5M | $346.3M | $270.8M | $370.9M | $793.1M | $610.0M |
Bicycle Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$17.8M | -$14.8M | -$86.1M | -$60.6M | -$164.7M | -$249.7M |
| Cash From Investing | -$1.2M | -$2.0M | -$19.0M | -$2.9M | -$1.2M | -$2.4M |
| Cash From Financing | $62.8M | $320.7M | $6.7M | $250.0M | $519.8M | -$131,000 |
| Free Cash Flow | -$19.0M | -$16.8M | -$105.1M | -$63.6M | -$166.0M | -$252.0M |
Figures from Bicycle Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bicycle Therapeutics financials page for every line item.
Bicycle Therapeutics Company Profile
| Ticker | BCYC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, United Kingdom |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001761612 |
Frequently Asked Questions
What was Bicycle Therapeutics' revenue in fiscal 2025?
Bicycle Therapeutics (BCYC) reported revenue of $72.6M for fiscal 2025.
What is Bicycle Therapeutics' annual revenue history?
Bicycle Therapeutics' annual revenue by fiscal year: 2020: $10.4M; 2021: $11.7M; 2022: $14.5M; 2023: $27.0M; 2024: $35.3M; 2025: $72.6M.
What was Bicycle Therapeutics' net income in fiscal 2025?
Bicycle Therapeutics reported net income of -$219.0M for fiscal 2025.
What was Bicycle Therapeutics' earnings per share (EPS) in fiscal 2025?
Bicycle Therapeutics' diluted EPS was -$3.16 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bicycle Therapeutics generate in fiscal 2025?
Bicycle Therapeutics generated -$252.0M of free cash flow in fiscal 2025.
What was Bicycle Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bicycle Therapeutics reported revenue of $629,000.
How many shares of Bicycle Therapeutics are outstanding?
Bicycle Therapeutics reported a weighted average of 69.8 million basic shares outstanding in 2026 Q2.
What is Bicycle Therapeutics' market cap?
Based on its latest closing price, Bicycle Therapeutics (BCYC) has a market capitalization of about $253.4M.
When does Bicycle Therapeutics' fiscal year end?
Bicycle Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Bicycle Therapeutics headquartered?
Bicycle Therapeutics lists its business address in Cambridge, United Kingdom in its SEC filings.